TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00001573
Drug: SU101
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00416143
Drug: prednisone - oral corticosteroid 1mg/kg/D for 1 week
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00832182
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Study: NCT03285711
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 mg tablet administered orally once daily
Study: NCT00106418
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT03285711
Drug: Lanraplenib
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tablet administered orally once daily
Study: NCT03285711
Drug: Filgotinib placebo
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet administered orally once daily
Study: NCT03285711
Drug: Lanraplenib placebo
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02600117
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg, oral, once a day
Study: NCT00183924
Drug: Estramustine
Normalized name: Estramustine
DrugBank: Estramustine (DB01196)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00183924
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004817
Drug: valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00136981
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00136981
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02452047
Drug: Imipenem+Cilastatin/Relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
Study: NCT02452047
Drug: Colistimethate sodium (CMS)
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
Study: NCT00183924
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02452047
Drug: Imipenem+Cilastatin
Normalized name: cilastatin / imipenem
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
Study: NCT00617253
Drug: recombinant interleukin-21
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mcg/kg, s.c. injection
Study: NCT02908334
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg/day sertraline
Study: NCT03312738
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
Study: NCT00617253
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hard gelatine capsules, 12.5 mg
Study: NCT00617253
Drug: recombinant interleukin-21
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg/kg, s.c. injection
Study: NCT00617253
Drug: recombinant interleukin-21
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mcg/kg, s.c. injection
Study: NCT00617253
Drug: recombinant interleukin-21
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mcg/kg, s.c. injection
Study: NCT03312738
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
Study: NCT03312738
Drug: Everolimus Placebo
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
Study: NCT00017641
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017641
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00153062
Drug: Aggrenox
Normalized name: Aggrenox
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg aspirin, 200 mg dipyridamole
Study: NCT00153062
Drug: Clopidogrel placebo
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: placebo
Study: NCT00153062
Drug: Micardis
Normalized name: Micardis
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg micardis
Study: NCT00153062
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg clopidogrel
Study: NCT00530907
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.3 mg/kg by mouth daily x 28 days
Study: NCT00530907
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg/kg by vein over 90 minutes every 2 weeks
Study: NCT01511991
Drug: Sevoflurane dosage titration
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
Study: NCT02410759
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 women with atonic PPH will receive Carbetocin 100 µgm IM
Study: NCT02410759
Drug: Ergometrine
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
Study: NCT02112032
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
Study: NCT00734097
Drug: Esomeprazole 40 mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day
Study: NCT00571675
Drug: AT-101, prednisone and docetaxel
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
Study: NCT00571675
Drug: placebo, prednisone and docetaxel
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
Study: NCT01863771
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
Study: NCT01715831
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
Study: NCT05024448
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration, 60mg/d for 10d
Study: NCT04552977
Drug: fluzoparil
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PARP1 inhibitor
Study: NCT04552977
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an alkylating chemotherapeutic agent
Study: NCT00114959
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m\^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule.
Study: NCT01748370
Drug: Vitamin D supplementation in hypogonadal men
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683005
Drug: ledipasvir/sofosbuvir
Normalized name: LEDIPASVIR/SOFOSBUVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
Study: NCT02940405
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
Study: NCT01748370
Drug: Vitamin D supplementation in eugonadal men
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02860780
Drug: prexasertib
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02860780
Drug: ralimetinib
Normalized name: Ralimetinib
DrugBank: Ralimetinib (DB11787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03341767
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
Study: NCT01346865
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg bid
Study: NCT02337491
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02337491
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003146
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003146
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003146
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04200885
Drug: Dexamethasone 21-Phosphate
Normalized name: Betamethasone 21-phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injections were administered in the immediate preoperative period as a single shot.
Study: NCT04320498
Drug: Anrecta
Normalized name: Tabrecta
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
Study: NCT03237637
Drug: oral propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
Study: NCT03885947
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic Acid (VPA) expanded cord blood stem cells
Study: NCT03885947
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 150 mg/m2
Study: NCT03885947
Drug: cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytoxan 50 mg/m2
Study: NCT03237637
Drug: oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
Study: NCT00819962
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT03885947
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa 10 mg/m2
Study: NCT00144677
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00144677
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01429090
Drug: methantheline solution
Normalized name: METHANTHELINE
DrugBank: Methantheline (DB00940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration 100 ml methantheline solution (100 mg methantheline bromide)
Study: NCT00114959
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
Study: NCT01459926
Drug: TD-1211
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily
Study: NCT01459926
Drug: TD-1211
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily
Study: NCT00596427
Drug: Colesevelam HCL
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCL 625 mg: 3 tablets twice per day
Study: NCT02018133
Drug: Vitamin D 2mg daily for 2 weeks oral paricalcitol
Normalized name: ergocalciferol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vitamin D 2 capsules daily
Study: NCT02713997
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
Study: NCT02713997
Drug: Alpha 1-Antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
Study: NCT01774981
Drug: LY3016859
Normalized name: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02669875
Drug: Serelaxin
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
Study: NCT00599911
Drug: Lu AA24530
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral, once daily for 6 weeks
Study: NCT00599911
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per oral, once daily for 6 weeks
Study: NCT03251378
Drug: Fruquintinib (HMPL-013)
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Study: NCT04217629
Drug: SY-005
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
Study: NCT00239148
Drug: E1 and G1
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein Injection [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02755753
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
Study: NCT02755753
Drug: Rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
Study: NCT02755753
Drug: Rebamipide-placebo
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
Study: NCT03758729
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
Study: NCT00129337
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
Study: NCT00670982
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously every 2 weeks
Study: NCT00670982
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously once a week
Study: NCT00670982
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously once a week
Study: NCT00935792
Drug: alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously
Study: NCT00935792
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00203775
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00821535
Drug: maraviroc (Selzentry, Celsentri)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
Study: NCT05306990
Drug: Atorvastatin 40 Mg Oral Tablet
Normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients followed up for 3 months
Study: NCT01126892
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014690
Drug: plevitrexed
Normalized name: Plevitrexed
DrugBank: Plevitrexed (DB06163)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00014690
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02556723
Drug: Intravitreal injections of ziv-aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
Study: NCT01007552
Drug: Gemcitabine, Capecitabine and Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
Study: NCT00894751
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine general anesthesia for MRI
Study: NCT00894751
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol general anesthesia for MRI
Study: NCT04361630
Drug: FGF 2
Normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.